A Systematic Patient‐Derived Xenograft Based Solution for Preclinical Biomarker Discovery

Tumor heterogeneity is a major hurdle for cancer treatment success. To effectively enroll patients in clinical trials, the identification of predictive biomarkers at the preclinical stage is crucial. The use of patient-derived xenograft (PDX) tumor models facilitates the identification of biomarkers that predict the tumor’s response to therapy. In addition, the assessment of PDX models on broad screening platforms such as 3D culture and in vivo mouse clinical trials (humanized and immunodeficient) accelerates compound evaluation.

Nach Vereinbarung: Ja
Referent: Herr Ph.D. Vincent Vuaroqueaux
Sprache: Englisch
Mehr über Charles River
Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.